MEDIA RELEASE PR35676
Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the
Intellectual Property Offered for Sale at the September 30, 2009 Auction
WELLESLEY HILLS, Mass., Aug. 12 /PRNewswire-AsiaNet/ --
Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-07034 Therapeutics - CNS Phase 2 will be
part of the intellectual property offered for sale at the September 30, 2009 auction.
The PRX-07034 Therapeutics - CNS Phase 2 is a small molecule, oral 5HT6 antagonist for cognitive impairment
associated with schizophrenia (CIAS). The Company has completed Phase 1 in obesity with racemic compound
and completed Phase 1 with chiral compound. It has an open IND and a significant quantity of chiral API available.
The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction on
September 30, 2009.
Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's
Office - jffinnjr@earthlink.net or +1-781-237-8840. They will then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public
Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for
distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors
and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy
cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include
Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at +1-781-237-8840 or jffinnjr@earthlink.net
SOURCE: Joseph F. Finn, Jr., C.P.A.
CONTACT: Joseph F. Finn, Jr.,
C.P.A.,
+1-781-237-8840,
jffinnjr@earthlink.net
NEWS 
